查看購物車
  • Simplified Chinese
  • English
  • Japanese
胃癌市場:KOL的洞察
市場調查報告書
商品編碼
1751659

胃癌市場:KOL的洞察

KOL Insight - Gastric Cancer
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2個工作天內

價格
簡介目錄

這份全面的報告匯集了12位美國和歐洲關鍵意見領袖 (KOL) 對胃癌 (GC) 治療現狀和未來的見解。報告探討了曲妥珠單抗和Enhertu等HER2標靶療法的持續發展，評估了Keytruda、Opdivo和Tevinbra等免疫腫瘤藥物的臨床和商業意義，並評估了zolbetuximab、bemarituzumab和zanidatamab等新興療法的未來潛力。報告探討了GC管理中的關鍵課題、生物標記在指導治療中日益增強的作用，以及對新型聯合治療策略的預期。報告將深入分析已核准和正在研發的療法，並結合專家對臨床試驗結果和未來治療趨勢的見解。

關鍵問題

  • 1.目前胃癌治療有哪些未被滿足的需求？
  • 2.胃癌患者常見的第一線和第二線治療有哪些？
  • 3.HER2狀態如何影響胃癌的治療選擇？
  • 4.Opdivo、Keytruda、Tevinbra、Bayloi等新核准的藥物如何影響治療策略？
  • 5.哪一種免疫腫瘤學方法在胃癌治療中最具前景？
  • 6.生物標記如何用於指導胃癌治療？
  • 7.專家對貝馬利珠單抗和佐貝妥昔單抗等新型標靶療法有何看法？
  • 8.您預期未來3到5年胃癌治療模式將如何改變？

領導品牌

  • ARX788
  • BAVENCIO(Avelumab)
  • bemaritsuzumabu
  • seraraserutibu
  • CYRAMZA(Ramucirumab)
  • domachinosutatto
  • enherutu(Trastuzumab·derukusutekan)
  • ebopaseputo
  • Herceptin(Trastuzumab)
  • imufinji(Durvalumab)
  • ipataseruchibu
  • yaboi(Ipilimumab)
  • KEYTRUDA(Pembrolizumab)
  • LENVIMA(Lenvatinib)
  • Margetuximab
  • Ontruzant(Trastuzumab)
  • Opdivo(Nivolumab)
  • riratorimabu
  • rimubumabu(katumakisomabu)
  • rechifanrimabu
  • ruburaka(rukaparibu)
  • suchibaga(Regorafenib)
  • teboterimabu
  • TECENTRIQ(Atezolizumab)
  • tebinbura(chisurizumabu)
  • tsukisa(tsukachinibu)
  • bairoi(zorubetsukishimabu)
  • yaboi(Ipilimumab)
  • zanidatamabu

研究方法：

"治療趨勢" 報告透過對全球領先的關鍵意見領袖 (KOL) 進行深入訪談，探討關鍵疾病領域的當前和未來治療前景。 KOL 的篩選標準非常嚴格，包括全球聲譽、臨床專業知識以及在其治療領域的影響力。每次訪談都配有精心設計的討論指南。這些指南由我們與 KOL 合作開發，並由行業專家進行同行評審，以確保所提問題全面且與當前市場動態相關。在每份報告發布後，我們會持續進行12個月的市場監測，並及時向您提供 KOL 提供的重要新聞事件、市場變化和市場發展的最新資訊。

我們的報告有何特別之處？

FirstWord Reports 是值得信賴的行業領導者，專注於製藥業，為生物製藥專業人士和決策者提供詳細且切實可行的洞察。我們擁有深厚的行業知識，能夠為您提供相關且有價值的洞察，幫助您掌握新興趨勢，有​​效應對複雜課題。我們的報告以廣泛的研究以及來自頂尖專家和關鍵意見領袖 (KOL) 的獨立、公正的見解為後盾，能夠提供您所需的準確性和可靠性。獨家訪談和數據，以及持續的市場監測，確保您全面了解市場動態。我們的報告涵蓋 40 多個動態疾病領域，包含包括關鍵意見領袖洞察和定量醫生調查在內的醫生情報，以及行業專家對醫療事務、數位健康、銷售與行銷、市場准入和其他領域問題的看法，使您能夠做出更明智的數據驅動決策，從而在快速變化的行業中保持競爭力。

簡介目錄

This comprehensive report delves into the current and future landscape of gastric cancer (GC) treatments, offering insights from 12 key opinion leaders (KOLs) across the US and Europe. It examines the evolving roles of HER2-targeted therapies such as trastuzumab and Enhertu, assesses the clinical and commercial implications of immuno-oncology agents including Keytruda, Opdivo, and Tevimbra, and evaluates the promise of emerging therapies like zolbetuximab, bemarituzumab, and zanidatamab. The report explores key challenges in GC management, the growing role of biomarkers in guiding treatment, and expectations for new combination strategies. Gain a detailed understanding of both approved and pipeline therapies, supported by expert insights on trial outcomes and future treatment dynamics.

Key Questions Answered:

  • 1. What are the biggest unmet needs in gastric cancer treatment today?
  • 2. How are gastric cancer patients typically treated in first- and second-line settings?
  • 3. How is HER2 status influencing therapy selection in gastric cancer?
  • 4. What impact have new approvals like Opdivo, Keytruda, Tevimbra, and Vyloy had on treatment strategies?
  • 5. Which immuno-oncology approaches show the most promise in gastric cancer?
  • 6. How are biomarkers being used to guide treatment decisions in GC?
  • 7. What are expert views on emerging targeted therapies like bemarituzumab and zolbetuximab?
  • 8. How is the gastric cancer treatment landscape expected to evolve over the next 3-5 years?

Key Brands:

  • ARX788
  • Bavencio (avelumab)
  • Bemarituzumab
  • Ceralasertib
  • Cyramza (ramucirumab)
  • Domatinostat
  • Enhertu (trastuzumab deruxtecan)
  • Evorpacept
  • Herceptin (trastuzumab)
  • Imfinzi (durvalumab)
  • Ipatasertib
  • Yervoy (ipilimumab)
  • Keytruda (pembrolizumab)
  • Lenvima (lenvatinib)
  • Margetuximab
  • Ontruzant (trastuzumab)
  • Opdivo (nivolumab)
  • Relatlimab
  • Removab (catumaxomab)
  • Retifanlimab
  • Rubraca (rucaparib)
  • Stivarga (regorafenib)
  • Tebotelimab
  • Tecentriq (atezolizumab)
  • Tevimbra (tislelizumab)
  • Tukysa (tucatinib)
  • Vyloy (zolbetuximab)
  • Yervoy (ipilimumab)
  • Zanidatamab

Methodology:

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.